ACADIA Pharmaceuticals, Inc. to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present data from its previously reported Phase II trial with pimavanserin for Parkinson’s disease psychosis (PDP) at the 60th American Academy of Neurology Annual Meeting on April 16, 2008 in Chicago, Illinois.